Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting

Molecular Partners ( (MOLN) ) just unveiled an announcement.

On December 7, 2025, Molecular Partners presented updated data from their ongoing Phase 1/2a trial of MP0533, a multispecific T-cell engager, at the ASH Annual Meeting. The trial, which involves patients with relapsed/refractory acute myeloid leukemia (AML), demonstrated promising clinical benefits with an acceptable safety profile across various dosing regimens. The data indicated that MP0533 could significantly improve treatment options for AML patients, particularly those with low disease burden, and supports further investigation in a Phase 2 setting.

The most recent analyst rating on (MOLN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Spark’s Take on MOLN Stock

According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.

The overall stock score of 51 reflects significant financial challenges, including declining revenue and negative profitability margins, which are partially offset by positive technical indicators suggesting short-term bullish momentum. The negative P/E ratio and lack of dividend yield further weigh on the valuation.

To see Spark’s full report on MOLN stock, click here.

More about Molecular Partners

Molecular Partners AG is a clinical-stage biotech company specializing in the development of DARPin therapeutics, a new class of custom-built protein drugs. The company focuses on oncology and leverages its proprietary DARPin platform to address medical challenges unmet by other drug modalities. Founded in 2004, Molecular Partners operates from Zurich, Switzerland, and Concord, Massachusetts, USA.

Average Trading Volume: 5,493

Technical Sentiment Signal: Hold

Current Market Cap: $170.3M

Learn more about MOLN stock on TipRanks’ Stock Analysis page.